RIH to Recruit Individuals at Known Risk for Developing Alzheimer’s for New Drug Study

July 15, 2020

Researchers at Rhode Island Hospital’s Alzheimer’s Disease and Memory Disorders Center are currently recruiting volunteer participants for the AHEAD 3-45 study, an innovative Phase III clinical trial of an anti-amyloid antibody, BAN2401, for individuals with normal memory function at risk for developing Alzheimer’s disease.  The purpose of the study is to investigate whether BAN2401, which works by selectively targeting abnormal build-up of amyloid-beta in the brain, can prevent the onset of Alzheimer’s disease. 
The AHEAD 3-45 study is, in fact, 2 trials for healthy individuals between the ages of 55 and 80 years, without current memory or thinking issues – the AHEAD-3 trial for those with intermediate levels of amyloid beta and the AHEAD-45 trial for individuals with higher levels of amyloid, as measured by a Positron Emission Technology (PET) brain scan. In this placebo-controlled study, either BAN 2401 or a placebo will be given intravenously 1-2 times a month, depending upon the level of brain amyloid measured by PET scan at the beginning of the study. Everyone participating must have a study partner who can come to some of the visits throughout the study, which lasts about 4 years.
“The AHEAD study will provide valuable information on a drug that shows real promise to be a key component of treatment to combat Alzheimer’s disease,” said Dr. Jonathan Drake, Associate Director of the Alzheimer’s Disease and Memory Disorders Center and principal investigator for the AHEAD 3-45 study. “Many previous clinical trials of investigational agents that targeted reduction of brain amyloid have not succeeded; however, Biogen’s recent decision to pursue FDA approval for aducanumab, another anti-amyloid antibody, has rekindled enthusiasm in this class of investigational drugs. As Biogen seeks regulatory approval for aducanumab, we feel a renewed hope that new treatments are within our reach. We invite individuals at known risk for Alzheimer’s disease to consider participation in our research program. We value our Citizen Scientist® volunteers and the work they undertake with us as research partners. This research can’t happen without them and their selfless desire to help find an end to this fatal disease.”    
Interested volunteers should contact Dr. Drake or Recruitment Specialist Terry Fogerty the Rhode Island Alzheimer’s Disease and Memory Disorders Center at 1-844-5MEMORY or by email at memory@lifespan.org.
 

Media Contact

Christina Spaight O'Reilly

Senior Public Relations Officer
Rhode Island Hospital
401-444-6421
christina.oreilly@lifespan.org